High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices

Blood

Volumn 89, Issue 3, 1997, Pages 801-813

  Horning, Sandra J ^a,b   Chao, Nelson J ^a   Negrin, Robert S ^a   Hoppe, Richard T ^a   Long, Gwynn D ^a   Hu, Wendy W ^a   Wong, Ruby M ^a   Brown, Byron W ^a   Blume, Karl G ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; VINBLASTINE;

ARTICLE; CELL TRANSPLANTATION; DISEASE COURSE; FEMALE; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYELODYSPLASIA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 0030938978     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.3.801     Document Type: Article

References (45)

1. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 13:1080, 1995
2. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478, 1992
3. Connors JM, Klimo P: MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease. Semin Hematol 35, 1987
4. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 104:739, 1986
5. Bonadonna G, Santoro A, Gianni AM, Viviani S, Siena S, Bregni M, Zucali R, Lombardi F, Bonfante V, Gianni L: Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. Ann Oncol 1:9, 1991
6. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VJ: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210, 1992
7. Gribben JG, Linch DC, Singer CR, McMillan AK, Jarrett M, Goldstone AH: Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73:340, 1989
8. Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS, Shina DC, Glasgow GP, Griffith RC, Lamb CW: Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73:2086, 1989
9. Burns LJ, Daniels KA, McGlave PB, Miller WJ, Ramsay NK, Kersey JH, Weisdorf DJ: Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: Factors predictive of prolonged survival. Bone Marrow Transplant 16:13, 1995
10. Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P: High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report. J Clin Oncol 6:1411, 1988
11. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81:1137, 1993
12. Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, Scott JG, McCrae J, Murray C, Pantalony D, Sutcliffe SB, Keating A: High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 11:704, 1993
13. Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, Di NM, Magni M, Peccatori F, Valagussa P, Bonadonna G: High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease - a 6-year update. Ann Oncol 4:889, 1993
14. Horning SJ, Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG: Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12:2552, 1994
15. Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G: High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 104:163, 1986
16. Jones RJ, Piantadosi S, Mann RB, Ambinder RF, Seifter EJ, Vriesendorp HM, Abeloff MD, Burns WH, May WS, Rowley SD: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8:527, 1990
17. Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 85:1381, 1995
18. Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Eberly S, Sherman M, Tanner MA, Constine LS, DiPersio JF: One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 11:2351, 1993
19. Reece DE, Barnett MJ, Connors JM, Fairey RN, Greer JP, Herzig GP, Herzig RH, Klingemann HG, O'Reilly SE, Shepherd JD, Spinelli JJ, Voss NJ, Wolff SN, Phillips GL: Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 9:1871, 1991
20. Yahalom J, Gulati SC, Toia M, Maslak P, McCarron EG, O'Brien JP, Portlock CS, Straus DJ, Phillips J, Fuks Z: Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 11:1062, 1993
21. Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke KA, Armitage JO: High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients. Ann Oncol 4:767, 1993
22. Blume KG, Forman SJ, O'Donnell MR, Doroshow JH, Krance RA, Nademanee AP, Snyder DS, Schmidt GM, Fahey JL, Metter GE, Hill LR, Findley DO, Sniecinski IJ: Total body irradiation and high-dose etoposide: A new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69:1015, 1987
23. Chao NJ, Kastrissios H, Long GD, Negrin RS, Horning SJ, Wong RM, Blaschke TF, Blume KG: A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer 75:1354, 1995
24. Hansen HH, Selawry OS, Pajak TF, Spurr CL, Falkson G, Brunner K, Cuttner J, Nissen NI, Holland JF: The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. Cancer 47:14, 1981
25. Chao NJ, Nademanee AP, Long GD, Schmidt GM, Donlon TA, Parker P, Slovak ML, Nagasawa LS, Blume KG, Forman SJ: Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol 9:1575, 1991
26. Thomas ED, Storb R: Technique for human marrow grafting. Blood 35:507, 1970
27. Negrin RS, Pesando J: Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations. J Clin Oncol 12:1021, 1994
28. Advani R, Chao NJ, Horning SJ, Blume KG, Ahn DK, Lamborn KR, Fleming NC, Bonnem EM, Greenberg PL: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hematopoietic stem cell transplantation for lymphoma. Ann Intern Med 116:183, 1992
29. Poen JC, Hoppe RT, Horning SJ: High dose therapy and autologous hematopoietic progenitor cell transplantation for relapsed/refractory Hodgkin's disease: The impact of local/regional radiotherapy on patterns of failure and survival. (submitted)
30. Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ, Connors JM, O'Reilly SE, Spinelli JJ, Phillips GL: High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/-P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451, 1995
31. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ, Voss N, Chan K, Phillips GL: Intensive therapy with cyclophosphamide, carmustine, etoposide +/-cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 83:1193, 1994
32. Yuen AR, Rosenberg SA, Hoppe RT, Horning SJ: Comparison between autologous hematopoietic progenitor cell transplantation and conventional salvage therapy for recurrent or refractory Hodgkin's disease. (submitted)
33. Desch CE, Lasala MR, Smith TJ, Hillner BE: The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol 10:200, 1992
34. Weaver CH, Appelbaum FR, Petersen FB, Clift R, Singer J, Press O, Bensinger W, Bianco J, Martin P, Anasetti C, Badger C, Deeg J, Dony K, Hansen JA, Petersdorf E, Rowley S, Storb R, Sullivan K, Witherspoon R, Weiden P, Buckner CD: High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 11:1329, 1993
35. Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE: Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study. J Clin Oncol 8:648, 1990
36. Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J, Clift RA, Lilleby K, Anasetti C, Martin P, Storb R, Chauncey T, Doney K, Sullivan K, Appelbaum FR: High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 13:596, 1995
37. Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB: Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 7:179, 1989
38. Carella AM: The place of high-dose therapy with autologous stem cell transplantation in primary treatment of Hodgkin's disease. Ann Oncol 1:15, 1993
39. Whitcomb ME, Schwartz MI, Keller AR, Flannery EP, Blom J: Hodgkin's disease of the lung. Am Rev Respir Dis 106:79, 1972
40. Grimwade DJ, Chopra R, King A, Shaw P, Pearce R, Linch DC, Goldstone AH: Detection and significance of pulmonary Hodgkin's disease at autologous bone marrow transplantation. Bone Marrow Transplant 13:173, 1994
41. Bierman P, Anderson J, Vose J, Freeman M, Bishop M, Kessinger A, Armitage J: High-dose chemotherapy with autologous hematopoietic rescue for Hodgkin's disease following first relapse after chemotherapy. Proc Am Soc Clin Oncol 12:1238 A, 1993
42. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P, Freedman AS, Nadler LM: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535, 1994
43. Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ: Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 84:957, 1994
44. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG, Tarantolo SR, Weisenburger DD, Kessinger A, Armitage JO: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527, 1994
45. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ: Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood 83:3780, 1994